RxDoctor Payments Data

Maria Ale Castro, MD

Infectious Disease · Miami Shores, FLNPI 1295747772

Payments from drug & device makers

$897in general payments, 2019–2025

Across 25 payments — averaging $35.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$577
  • Gilead$290
  • Johnson & Johnson$17
  • Merck$13

What the payments were for

  • Food & beverage$88499%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company13$577
Gilead10$290
Johnson & Johnson1$17
Merck1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$897 in reported general payments places this provider in the 50th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$280,330
Medicare patients
584
Services billed
2,999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala361$1,407,160
GenvoyaElviteg/Cob/Emtri/Tenof Alafen91$377,502
TriumeqAbacavir/Dolutegravir/Lamivudi79$291,377
TivicayDolutegravir Sodium95$263,614
DovatoDolutegravir Sodium/Lamivudine84$253,963
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf48$219,898
JulucaDolutegravir/Rilpivirine60$214,278
PrezcobixDarunavir/Cobicistat72$178,027
DescovyEmtricitabine/Tenofov Alafenam47$105,738
OdefseyEmtricitab/Rilpiviri/Tenof Ala23$81,447
SelzentryMaraviroc12$49,563
Isentress HdRaltegravir Potassium16$34,505
EvotazAtazanavir Sulfate/Cobicistat22$34,121
PrezistaDarunavir14$33,958
Etravirine20$21,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$290$1,890,400499 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Dovato, Juluca$577$1,023,232318 claims
Johnson & JohnsonPrezcobix$17$178,02772 claims
MerckIsentress Hd$13$34,50516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Miami Shores

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →